Sosei Group Corp., of Tokyo, said the LANTERN study demonstrated that once-daily Ultibro Breezhaler was superior in reducing exacerbations (by 31 percent) and improving lung function (p < 0.001) compared to twice-daily Seretide Accuhaler (salmeterol/fluticasone).